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The Epstein–Barr virus nuclear antigen (EBNA)-6 protein is essential for Epstein–Barr virus (EBV)-induced immortalization of primary
human B-lymphocytes in vitro. In this study, fusion proteins of EBNA-6 with green fluorescent protein (GFP) have been used to characterize
its nuclear localization and organization within the nucleus. EBNA-6 associates with nuclear structures and in immunofluorescence
demonstrate a punctate staining pattern. Herein, we show that the association of EBNA-6 with these nuclear structures was maintained
throughout the cell cycle and with the use of GFP-E6 deletion mutants, that the region amino acids 733–808 of EBNA-6 contains a domain
that can influence the association of EBNA-6 with these nuclear structures. Co-immunofluorescence and confocal analyses demonstrated that
EBNA-6 and EBNA-3 co-localize in the nucleus of cells. Expression of EBNA-6, but not EBNA-3, caused a redistribution of nuclear
survival of motor neurons protein (SMN) to the EBNA-6 containing nuclear structures resulting in co-localization of SMN with EBNA-6.
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The Epstein–Barr virus (EBV) is a DNA tumor virus that
has the capacity to infect and transform B-lymphocytes.
Following infection, the coordinate expression of several
viral nuclear antigens (Epstein–Barr virus nuclear antigens,
EBNAs) and membrane proteins (LMP-1 and -2) act to
maintain B-cell growth transformation (for review, see
Kieff, 1996). The EBNA-3 family of proteins, EBNAs 3,
4, and 6 (also called EBNA 3A, 3B and 3C, respectively),
are thought to act as transcriptional regulators that poten-
tially play multiple roles in the transformation and immor-
talization process. They are large hydrophilic, proline-rich,
charged proteins that share a similar genomic organization
and significant amino acid identity.
Analysis of the EBNA-6 amino acid sequence has
revealed features common to many viral and cellular tran-0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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resembles a basic DNA binding domain adjacent to a
potential leucine zipper motif (b-zip) and regions (rich in
acidic, proline, and glutamine residues) that are good
candidates for domains involved in the modulation of
transcription (Bain et al., 1996; Radkov et al., 1997). A
transactivation domain rich in glutamine/proline residues
that has similarities to the mammalian transcription factor
Sp1 has been mapped to amino acids 724–826 (Marshall
and Sample, 1995). A number of protein partners for
EBNA-6 have been identified, including (1) the DNA
binding protein, RBP-J6/RBP-2N that binds EBNA-6
through amino acids 182–231 (Johannsen et al., 1996;
Robertson et al., 1995; Young et al., 1997; Zhao et al.,
1996); (2) a histone deacetylase, thought to mediate tran-
scriptional repression, binds the first 203 amino acids of
EBNA-6 (Radkov et al., 1999); (3) prothymosin a (Cotter
and Robertson, 2000), a protein implicated in cell prolifer-
ation and division (Goodall et al., 1986; Rodriguez et al.,
1998); (4) the putative RNA helicase DP103 binds to
EBNA-6 through amino acids 534–778 (Grundhoff et al.,
1999; (5) the human metastatic suppressor Nm23-H1 (Sub-
ramanian et al., 2001). In addition, EBNA-6 has been
Fig. 1. Schematic representation of GFP-EBNA-6 deletion mutants. The position of computer predicted NLS are shown as black boxes. The RBP-2N binding
site, leucine zipper, HDAC binding site, proline rich regions, transactivation domain, DP103 binding region, and Prothymosin a binding region are indicated,
and the corresponding amino acid locations are also shown.
Fig. 2. Western blot analysis of HeLa cells expressing the GFP-EBNA-6
constructs. Total cell lysates were prepared from 1  106 transfected HeLa
cells and subjected to Western blot analysis using anti-GFP polyclonal
antibody. The location of some of the GFP-E6 fusion proteins is indicated
by the asterisks, and the molecular weight markers are shown.
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ate with activated (Ha-) ras in cotransformation assays and
can override Rb-mediated pathways (Allday et al., 1993).
More recently, EBNA-6 was shown to disrupt multiple cell
cycle checkpoints and induce nuclear division independent-
ly from cytokinesis, suggesting a role for EBNA-6 in cell
cycle regulation (Parker et al., 1996).
The eukaryotic nucleus is highly organized and contains
a variety of specialized subnuclear structures, including the
nucleolus, interchromatin granule speckles, promyelocytic
nuclear bodies (PML), coiled or ‘‘Cajal’’ bodies (CBs), and
gemini of coiled bodies or gems (Lamond and Earnshaw,
1998). Interchromatin speckles are observed with splicing
factors such as SC35 (Fu and Maniatis, 1990) and represent
aggregates of snRNPs and splicing factors (Spector, 1993).
Fig. 3. Nuclear localization patterns of EBNA-6 deletion mutants. Schematic diagram of the GFP-EBNA-6 constructs and their nuclear localization patterns in
HeLa cells are shown. The region of EBNA-6 that is involved in the binding of EBNA-6 to nuclear structures resulting in the appearance of speckles is shown
by the shaded box.
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Fig. 4. Nuclear localization patterns of regions of EBNA-6. (A) Schematic diagram of the GFP-EBNA-6 PCR constructs and their nuclear localization patterns
in HeLa cells are shown. The minimal region required for binding to nuclear structures is shown by the shaded box. (B) HeLa cells were co-transfected with
GFP-E6D1-206/941–992 and p3XFLAGCMV10-EBNA-6, and were then grown onto cover slips, fixed, and then stained with the anti-FLAG antibody and
anti-mouse Texas Red-X. The GFP-E6D1-206/941–992 fusion protein was visualized by direct fluorescence, whereas p3XFLAGCMV10-EBNA-6 was
visualized by indirect immunofluorescence. Regions of co-localization are seen by the yellow staining pattern in the overlay.
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and are thought to play a role in the regulation of gene
transcription (Doucas and Evans, 1996; Dyck et al., 1994;
Weis et al., 1994). Coiled bodies contain spliceosomal small
nuclear ribonucleoproteins (snRNPs), U3 small nucleolar
ribonucleoprotein (snoRNP), fibrillarin, NOPP140, and an
autoantigen called p80-coilin (Gall et al., 1995; Matera and
Frey, 1998). Coiled bodies vary in number from 1 to 10;
however, the number increases markedly in cancer cells
(Spector et al., 1992; Young et al., 2000). Gems are very
similar to coiled bodies in number, size, and distribution
pattern (Liu and Dreyfuss, 1996), and are often very closely
associated or even coincident with CBs (Carvalho et al.,Fig. 5. Association of EBNA-6 with subnuclear structures throughout the cell cyc
slips, then treated with mimosine (G1 phase), colcemid (metaphase), ICRF (G2/M,
(G1-S phase), nocodazole (G2 phase), or etoposide (G2/M, topoisomerase II inhibi
(A) and were analyzed by FACS (B).1999; Liu and Dreyfuss, 1996). Gems contain the survival
of motor neurons protein (SMN) (Liu and Dreyfuss, 1996),
which is encoded by the gene responsible for spinal mus-
cular atrophy (Lefebvre et al., 1995).
EBNA-6 is targeted exclusively to the cell nucleus, and
cellular fractionation experiments have shown that EBNA-6
is associated with the nuclear matrix, and to a lesser extent,
in the nucleoplasm (Petti et al., 1990). Sample and Kieff
(1990) showed that EBNA-6 localized to subnuclear gran-
ules within the cell nucleus. Although it has been known for
more than 10 years that EBNA-6 associates with discrete
nuclear structures, neither the components of these struc-
tures nor their functions have yet been determined. In thisle. HeLa cells expressing GFP-E6D1-206/941–992 were grown onto cover
topoisomerase II inhibitor), HU (S phase, replication inhibitor), aphidicolin
tor) for 24 h. The cells were then visualized by direct fluorescent microscopy
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for its association with the subnuclear structures and have
demonstrated that EBNA-6 co-localizes with EBNA-3 and
with the SMN protein.Results
Defining the region of EBNA-6 responsible for its
interaction with subnuclear granules
Because EBNA-6 always forms a speckled pattern within
the nucleus when expressed in cells, it is likely that this
interaction is important for the function of EBNA-6. It is
also likely that specific regions of EBNA-6 are involved in
its interaction with these nuclear structures. In order to mapFig. 6. EBNA-6 co-localizes with EBNA-3. HeLa cells expressing GFP-E6D1-206
cover slips, fixed, and then stained with the anti-FLAG antibody and anti-mouse T
direct fluorescence, whereas p3XFLAGCMV10-E3D1-279 was visualized by indi
staining pattern in the overlay.the region of EBNA-6 responsible for binding to these
structures, several deletion mutants, each containing at least
one NLS to ensure nuclear targeting, were constructed (Fig.
1). EBNA-6 is a nuclear protein that interacts with a variety
of different cellular proteins. In designing the EBNA-6
deletion mutants, we attempted to ensure disruption of each
of the known binding domains. Each of these constructs
were N-terminally linked to green fluorescent protein
(GFP), and their structures were confirmed by sequencing.
Expression of each of the constructs was established by
Western blotting (Fig. 2). All of the GFP-E6 constructs
displayed the expected molecular weights on SDS poly-
acrylamide gels.
Each of the deletion mutants were expressed in HeLa
cells and analyzed by confocal microscopy (Fig. 3). As
expected, the control GFP plasmid showed staining that was/941–992 were transfected with p3XFLAGCMV10-E3D1-279, grown onto
exas Red-X. The GFP-E6D1-206/941–992 fusion protein was visualized by
rect immunofluorescence. Regions of co-localization are seen by the yellow
Fig. 7. Subcellular localization of GFP-EBNA-6, FLAG-EBNA-3, GFP-
EBNA-1, and GFP. DG75 cells, transfected with plasmids encoding GFP-
EBNA-6, FLAG-EBNA-3, GFP-EBNA-1, or GFP were fractionated into
cytoplasmic (C), and nuclei (N) fractions. The nuclei were then disrupted
further in sequential digestions and salt extractions to collect nuclear
proteins after DNase treatment (NP), lipid membrane-bound proteins (L),
high-salt soluble proteins (HS), and matrix-associated proteins (M). The
final fraction (GW) was nuclear matrix that had been washed with
guanidine hydrochloride. The samples, as well as whole cell lysates (W),
were subjected to SDS-PAGE and were then analyzed by Western blot with
a-GFP, a-FLAG, or anti-EBNA-6 antibodies.
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whereas full-length GFP-EBNA-6 showed a nuclear punc-
tate staining pattern, together with a proportion of the
protein in a diffuse state within the nucleus. Constructs
containing deletions within the second half of EBNA-6
(GFP-E6D184–992, GFP-E6D441–992, GFP-E6D645–
992) showed diffuse nuclear staining without any nuclear
foci observed. In contrast, all of the EBNA-6 deletion
mutants containing amino acids 626–940 showed the char-
acteristic speckled/punctate fluorescent staining pattern.
Each of these constructs, except for GFP-E6D1-206/941–
992, also showed diffuse nuclear staining. These results
indicated that a region within amino acids 626–940 of
EBNA-6 was involved in the binding of EBNA-6 to nuclear
granules and the formation of the characteristic speckled
pattern.
To further refine the minimal region of EBNA-6 respon-
sible for its interaction with subnuclear structures, the region
of EBNA-6, encoding aa626–940, was further mapped by
PCR. There is only one NLS within this section of EBNA-6,
so the reverse primers either straddled the NLS sequence or
had the 4aa EBNA-6 NLS incorporated into them to ensure
that the GFP-fusion proteins would be targeted to the
nucleus. Each of the pBS-GFP plasmids containing PCR
amplified inserts were transiently transfected into HeLa
cells, and the association of the GFP-fusion proteins with
nuclear structures was determined by fluorescent microsco-
py (Fig. 4A). The region required for binding to the
subnuclear structures was reduced to aa733–808, as this
region was common to each of the constructs that were
capable of interacting with the nuclear substructures.
Interestingly, the GFP-E6D1-206/941–992 construct dis-
played predominantly a speckled/punctate fluorescent stain-
ing pattern with little diffuse nuclear background staining.
Because of the absence of significant diffuse nuclear staining
(which could complicate co-localization studies), the GFP-
E6D1-206/941–992 construct was used in subsequent co-
localization experiments. First, however, to confirm that the
GFP-E6D1-206/941–992 protein localized to the same
structures as the full-length EBNA-6 protein, a plasmid
encoding a FLAG-tagged full-length EBNA-6 protein was
prepared (p3XFLAGCMV10-EBNA-6). HeLa cells were
co-transfected with plasmids encoding the GFP-E6D1-206/
941–992 protein and the FLAG-tagged EBNA-6 protein,
and were then stained using a monoclonal antibody against
the FLAG epitope (Fig. 4B). There was extensive co-
localization between GFP-E6D1-206/941–992 and FLAG-
EBNA-6 in cells expressing both of these proteins. These
results show that the GFP-E6D1-206/941–992 protein local-
izes to the same structures as the full-length EBNA-6 protein.
Nuclear localization of EBNA-6 throughout the cell cycle
Generally, the association of EBNA-6 with subnuclear
granules appeared to be relatively consistent in LCLs and
cells transfected with GFP-E6, indicating that EBNA-6probably associates with these subnuclear structures
throughout the cell cycle. To test this, HeLa cells stably
expressing the GFP-E6D1-206/941–992 construct were
treated with a variety of drugs to arrest the cells in different
stages of the cell cycle, and the association of GFP-E6D1-
206/941–992 with subnuclear granules was determined by
fluorescent microscopy (Fig. 5A). The drugs used caused
the cells to arrest at G1, G1/S, S, G2, G2/M, or M phases of
the cell cycle, and this was determined by FACS (Fig. 5B).
Regardless of which phase of the cell cycle the arrest
occurred, GFP-E6D1-206/941–992 was always found to
be associated with subnuclear granules indicating that this
association was stable though out the cell cycle.
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EBNAs-3 and -6 are targeted exclusively to the cell
nucleus, and cellular fractionation experiments have shown
that they are present in the nucleoplasm and associate with
the nuclear matrix. Localization studies have also shown
that they localize to discrete subnuclear granules within the
cell nucleus, excluding the nucleoli (Petti et al., 1990;
Sample and Kieff, 1990); however, it is not known if each
of the EBNAs bind to the same structures or to different
nuclear structures.
As with EBNA-6, full-length EBNA-3 binds to nuclear
structures but also has a diffuse component that fills the
nucleoplasm and complicates co-localization studies. In
order to avoid this, a FLAG-tagged EBNA-3 construct
was prepared, which binds to nuclear structures but lacks
K.G. Krauer et al. / ViFig. 8. Co-localisation of EBNA-6 and SMN. HeLa cells expressing GFP-E6D1-2
anti-SMN antibody and anti-mouse Texas Red-X. The GFP-E6D1-206/941–992
visualized by indirect immunofluorescence. Regions of co-localization are seen b
expressing GFP-E6D1-206/941–992 that have been stained for SMN. Panels B a
co-localization of EBNA-6 with SMN.the diffuse component (FLAG-E3D1-279), and this was
used in co-localization studies with the GFP-E6D1-206/
941–992 construct. HeLa cells were co-transfected with
both constructs, fixed as described in the Materials and
methods, and were then stained using a monoclonal anti-
body against the FLAG epitope (Fig. 6). Although there was
extensive co-localization between GFP-E6D1-206/941–992
and FLAG-E3D1-279 in all cells expressing these proteins,
there were some regions where these proteins did not
overlap, and this was often more evident with EBNA-3
(arrowed). These results suggest that the majority of EBNA-
3 and EBNA-6 associate with the same structures, but that
there are some structures to which each of the proteins bind
independently. This co-localization was also confirmed
using full-length EBNA-3 and full-length EBNA-6 con-
structs (data not shown).06/941–992 were grown onto cover slips, fixed, and then stained with the
fusion protein was visualized by direct fluorescence, whereas SMN was
y the yellow staining pattern in the overlay. Panel A shows HeLa cells not
nd C show cells expressing GFP-E6D1-206/941–992 and almost complete
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EBNA-3 using another method, cells were fractionated and
the presence of EBNA-6 and EBNA-3 within these fractions
was determined. DG75 cells expressing GFP-EBNA-6,
FLAG-EBNA-3, GFP, or GFP-EBNA-1 (as a control) were
fractionated (see methods), and each of the extracts were
subjected to SDS page and Western blot analysis using either
a-GFP polyclonal antibody, a-FLAG, or a-EBNA-6 mono-
clonal antibodies (E6A10) (Fig. 7). GFP alone was present in
both the nucleus and cytoplasm, while the EBNA-1 protein
was, as expected, present throughout the nuclei and cyto-
plasmic fractions. A large proportion of the nuclear EBNA-1
was associated with the chromatin (released with high-salt
buffer) or associated with the matrix (M). GFP-EBNA-6 was
present primarily within the nucleus with a large proportion
(30%) of the nuclear EBNA-6 directly associated with the
matrix and being resistant to removal with guanidine hydro-
chloride washes. Like EBNA-6, FLAG-EBNA-3 was present
in the nucleus; however, it was primarily found in the
chromatin fraction (90%) with only 10% of the protein being
associated with the nuclear matrix fraction. EBNA-3 was lost
from the matrix following washing with guanidine hydro-
chloride suggesting that it may not interact directly with the
matrix. These results are similar to those found by Petti et al.
(1990) where they observed that EBNA-LP, -2, -3, and -6
were associated with the nuclear matrix, although they were
also found in the nucleoplasm and to a lesser extent in the
chromatin fractions.Fig. 9. Co-localization of EBNA-3 with SMN. HeLa cells, transfected with GFP-E
SMN antibody and anti-mouse Texas Red-X. The GFP-E3D1-279 fusion protei
indirect immunofluorescence.EBNA-6 recruits SMN to subnuclear structures
EBNA-6 has previously been shown to interact with the
DEAD box protein DP-103 (Grundhoff et al., 1999). Re-
cently, Charroux et al. (1999) showed that DP-103/Gemin3
interacted with SMN and was present in nuclear SMN-
complexes. We therefore addressed the possibility that
EBNA-6 may also associate with SMN. To determine the
degree of association between EBNA-6 and SMN, HeLa
cells stably expressing GFP-E6D1-206/941–992 were
grown on glass cover slips, fixed as described in the
Materials and methods, and were then stained using a
monoclonal antibody against SMN. Following processing,
cover slips were fixed onto slides and were then visualized
using a confocal microscope. Nuclear SMN (present in 2–
10 gems per cell) is usually only detected in a variable, but
small proportion of rapidly proliferating cells in culture
(Carvalho et al., 1999) and SMN gems were only observed
in 5% of the HeLa cells used in these studies (Fig. 8A).
Remarkably, following expression of GFP-E6D1-206/941–
992 in HeLa cells, nuclear SMN was observed in 20% of the
cells, and in these cells there were almost complete co-
localization of SMN with GFP-E6D1-206/941–992 (Figs.
8B, C). This co-localization was also confirmed using full-
length EBNA-6 and SMN (data not shown). Next, we
examined the co-localization of EBNA-3 with SMN. HeLa
cells were transfected with the FLAG-E3D1-279 construct,
fixed, and were then stained using a monoclonal antibody
318 (2004) 280–2943D1-279, were grown onto cover slips, fixed, and then stained with the anti-
n was visualized by direct fluorescence, whereas SMN was visualized by
Fig. 10. Co-immunoprecipitation of EBNA-6 and SMN. Cell lysates were
prepared from HeLa cells transfected with GFP-E6D1-206/941–992, and
GFP-E6D1-206/941–992 was immunoprecipitated with anti-GFP antibody.
The immunoprecipitate was separated by SDS gel electrophoresis, trans-
ferred to membranes, and then probed with anti-SMN antibody. The
location of SMN is shown by the arrow.
K.G. Krauer et al. / Virology 318 (2004) 280–294 289against SMN (Fig. 9). In this case, there was no association
between EBNA-3 and SMN, although EBNA-3 and EBNA-
6 are present on the same structures. Examination of broad
field images also showed that there was no increase in
nuclear SMN in EBNA-3-expressing cells. These results
indicate that EBNA-6, but not EBNA-3, was able to recruit
SMN to the EBNA-6 nuclear structures.
Given the co-localization of EBNA-6 with SMN and the
ability of EBNA-6 to recruit SMN, it was likely that EBNA-
6 could interact with SMN. To determine if there was an
interaction between EBNA-6 and SMN, co-immunoprecipi-
tations were performed from HeLa cells transfected with
GFP-E6D1-206/941–992. Cell lysates were prepared inFig. 11. SMN in Mutu cells. (A) MutuI and MutuIII BL cells were spotted onto cov
Texas Red-X, and were visualized by indirect immunofluorescence. Cells containi
and MutuIII cells were subjected to SDS gel electrophoresis and Western blotting uRIPA buffer and anti-GFP antibodies were used to immu-
noprecipitate GFP-EBNA-6. Following electrophoresis and
transfer of the immunoprecipitates, the membrane was
probed with an anti-SMN monoclonal antibody. The anti-
GFP antibody co-precipitated SMN from HeLa cells
expressing GFP-E6D1-206/941–992 (Fig. 10). The assay
was repeated three times and was also performed with GFP-
EBNA-6 (full-length) with similar results (data not shown).
These results showed that EBNA-6 is capable of specifically
binding to SMN.
SMN in Mutu cells
If the expression of EBNA-6 does influence the propor-
tion of cells containing nuclear SMN, then cell lines
expressing endogenous EBNA-6 would be expected to
contain a higher proportion of cells with nuclear SMN than
similar cells not expressing EBNA-6. To examine this,
MutuI cells (a Burkitt’s lymphoma [BL] cell line that does
not express EBNA-6) and MutuIII cells (that expresses all
the EBV latent antigens) were stained with anti-SMN
antibody and visualized by direct immunofluorescence
(Fig. 11A). These cell lines were also assayed for the
expression of EBNA proteins to ensure they retained their
latency I and III profiles (Fig. 11B). Similar to HeLa cells,
approximately 5% of the MutuI cells were observed to
contain nuclear SMN gems (arrowed), and these cells
contained between 2 and 10 gems per cell. However, the
MutuIII cells were found to have between 20% and 25% of
the cells positive for nuclear SMN (arrowed). Analysis of
SMN protein in MutuI and MutuIII cells by immunoblot
revealed that they both expressed similar amounts of total
SMN (data not shown), indicating that EBNA-6 did not
appear to cause an increase in the expression of SMN, but
rather an increase in the proportion of SMN in the nucleus
of cells.er slips, fixed, and then stained with the anti-SMN antibody and anti-mouse
ng nuclear SMN are indicated with arrows. (B) SDS extracts of both MutuI
sing MCr serum. The positions of EBNA-1, -2, -3, -4, and -6 are indicated.
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Although the function of the EBNA-3, -4, and -6 proteins
have not yet been fully characterized, it has been shown by
recombinant viruses that EBNAs-3 and -6 are essential for
viral transformation (Tomkinson et al., 1993). EBNA-6
forms stable complexes with RBP-Jn and RBP-2N, and
inhibits RBP-Jn/2N binding to DNA (Robertson et al.,
1995). The interaction of these latent proteins with RBP-
2N/RBP-Jn has lead to the suggestion that they play a role
in transcriptional regulation (Marshall and Sample, 1995).
Many studies have shown changes in cellular genes follow-
ing expression of the EBNA-3 family proteins, such as IL-
1h (Krauer et al., 1998) and pleckstrin (Kienzle et al., 1996).
As well, EBNA-6 has been shown to play a role in the
disruption of cell cycle checkpoints (Parker et al., 1996).
Nuclear factors involved in events, such as transcription, are
organized in distinct compartments within the nucleus. The
best-studied nuclear compartments are the nucleolus, splic-
ing-factor compartments, the Cajal body, PML bodies, and a
growing family of nuclear speckles (for review, see Dundr
and Misteli, 2001).
EBNA-6 associates with discrete nuclear structures,
which when viewed by immunofluorescence, appear as
speckles. The EBNA-6 speckles are stable throughout the
cell cycle (Fig. 5), as shown by blocking cells at the
different stages of the cell cycle using mimosine (G1 phase),
colcemid (metaphase), ICRF (G2/M, topoisomerase II in-
hibitor), HU (S phase, replication inhibitor), aphidicolin
(G1-S phase), nocodazole (G2 phase), and etoposide (G2/
M, topoisomerase II inhibitor). This suggests that the
structures to which EBNA-6 is bound are stable and do
not disassemble/reassemble during the cell cycle. The sub-
nuclear compartments to which EBNA-6 localizes are not
associated with the discrete nuclear bodies formed by Rb
tumor suppressor protein, the ATR protein (Ataxia Telangi-
ectasis RAD-related protein) or SC-35 (data not shown).
EBNA-6 is also not associated with PCNA, which is
thought to belong to a replicative complex that assembles
during G1/S phase of the cell cycle (data not shown). It is
likely that the structures to which EBNA-6 binds are novel
nuclear domains.
Using both deletion mutants of EBNA-6 and PCR-
generated constructs, linked to GFP, we have been able to
map the region of EBNA-6 that is involved in its interaction
with the subnuclear speckles. The region involved, amino
acids 733–808, occurs within a part of the protein that has
been shown to be essential for immortalization (Tomkinson
et al., 1993), suggesting that the interaction of EBNA-6 with
these nuclear substructures may be critical in the transfor-
mation of cells by EBV. This region of EBNA-6 is outside
known protein binding domains indicating that the associ-
ation of EBNA-6 with these subnuclear structures is unlike-
ly to be mediated through interaction with known EBNA-6
binding partners. The majority of EBNA-3 was released in
high-salt buffer indicating that it was not directly associatedwith the matrix, which indicates that the association of
EBNA-3 with the EBNA-6 subnuclear structures was likely
mediated through interaction with another protein rather
than through direct interaction with the nuclear matrix. Data
from Cludts and Farrell (1998) demonstrated that co-ex-
pression of EBNA-LP along with EBNA-3 increased the
association of EBNA-3 with the insoluble matrix fraction
signifying that the association of EBNA-3 with the nuclear
matrix may be mediated through interaction with some
different proteins, including EBNA-LP.
Immunofluorescence studies also revealed that EBNA-6
co-localized in nuclear structures with the SMN protein
(Fig. 8). Cytoplasmic SMN directly interacts with spliceo-
somal Sm proteins and facilitates their assembly onto U
snRNAs, whereas nuclear SMN appears to mediate recy-
cling of pre-mRNA splicing factors. Nuclear SMN may also
have a function related to gene regulation at the transcrip-
tional level since it interacts with the papillomavirus nuclear
transcription activator, E2 (Strasswimmer et al., 1999), and
with dp103/Gemin3 that was originally identified as a factor
that interacts with viral and cellular transcription factors
(Charroux et al., 1999). The association of EBNA-6 with
SMN may imply a role in either RNA processing or
transcriptional regulation. Other DNA viruses have already
been shown to express proteins capable of influencing RNA
processing as part of their transcription and replication
strategies.
The co-localization of EBNA-6 and SMN occurred on
the EBNA-6 nuclear structures, rather than in gems, where
nuclear SMN usually resides. The expression of EBNA-6
resulted in a recruitment of SMN to the EBNA-6 nuclear
structures suggesting that there maybe a direct interaction
between EBNA-6 and SMN. Barth et al. (2003) recently
demonstrated a direct interaction between EBNA-2 and
SMN; however, to achieve this required the use of deletion
mutants of SMN. We have demonstrated, by immunopre-
cipitation experiments, that EBNA-6 interacts with SMN;
however, both EBNA-6 and SMN have been shown to
directly interact with DP-103, and it is therefore possible
that EBNA-6 may bind to and recruit DP-103, which in turn
binds SMN. Expression of EBNA-6 in HeLa cells also
resulted in an increase in the number of cells containing
nuclear SMN. This was also seen in MutuIII cells, but not
MutuI cells, further implying that EBNA-6 was capable of
increasing nuclear SMN in cells. However, only 20% of
EBNA-6-expressing cells displayed nuclear SMN, suggest-
ing that the recruitment of SMN to the EBNA-6 nuclear
structures maybe cell cycle related.
An understanding of the structure and organization of
the cell nucleus is essential for studying the regulation of
cell function and nuclear processes and subsequently how
viruses subvert these processes. It is likely that EBV
utilizes EBNAs-3 and -6 to adapt the functioning of
specific nuclear structures to its needs. Further studies will
now be directed toward identifying the cellular proteins
present in the EBNA-6 nuclear structures and in character-
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proteins to these structures. Characterizing the nuclear
associations of the EBNAs-3 and -6 protein partners will
increase understanding of how these EBNAs function
within the cell and contribute to EBV infection and
transformation of B-lymphocytes.Materials and methods
Vector constructs
The correct orientation and insertion of fragments in each
of the deletion constructs of EBNA-6 (Fig. 1) were con-
firmed by restriction digest and DNA sequencing.
pBS-GFP-E6
The EBNA-6 cDNA fragment (B95.8 virus) was excised
from vector pGBT9-E6 (Young et al., 1997) using BsrGI
and BstEII. The excised fragment was then Klenow treated
and ligated into pBSGFP that had previously been restricted
with BsrGI and Klenow treated (pBSGFP was a gift from Dr
M. Vogel, Medicine, Microbiology and Hygine, Regensburg
University; pBS-GFP-E6 was originally prepared by D.
Young, QIMR).
pBS-GFPL
The pBSGFP plasmid was adapted to include a linker
containing the restriction enzyme sites: BsrGI, StuI, BamHI,
EcoRV, HpaI, XhoI, and NotI. This was prepared by
annealing 1 Ag of two self-complementary 41 base
oligomers (Custom made Life Technologies, Australia)
and then ligating this fragment into pBSGFP that had been
restricted with BsrGI and NotI.
pEBO-GFP-E6D207–393
A 561-bp fragment of EBNA-6 was excised from vector
pBSGFP-E6 by restriction with ClaI and HpaI. The ClaI
site was blunt ended with Klenow before the plasmid was
religated. The plasmid was then digested with HindIII and
NotI, and the resulting fragment was ligated into EBO-
pLPP that had been digested with HindIII and NotI. This
resulted in GFP being fused to EBNA-6 lacking amino
acids 207–393.
pEBO-GFP-E6D645–992
The vector pBSGFP-E6 was digested with EagI, result-
ing in the removal of a 1.1-kb fragment corresponding to
amino acids 645–992 of EBNA-6, and then the plasmid
religated. This plasmid was then digested with HindIII and
NotI, and the resulting fragment was ligated into EBO-pLPP
that had been digested with HindIII and NotI.
pEBO-GFP-E6D441–992
The vector pBSGFP-E6 was digested with BglII and then
religated. Then the plasmid was digested with HindIII andNotI, and the resulting fragment inserted into EBO-pLPP
restricted with the same enzymes resulting in the removal
amino acids 441–992 of EBNA-6.
pBS-GFP-E6D184–992
The vector pBSGFP-E6 was digested with XbaI, Klenow
treated, then digested with EcoRV, and religated. This
resulted in the removal of amino acids 184–992 of
EBNA-6.
pEBO-GFP-E6D394–624
The three internal NLS were removed from EBNA-6 by
excising a 696-bp fragment from the vector pBSGFP-E6
by restriction with ClaI and NarI. The restricted ends were
then Klenow treated and religated. The plasmid was then
digested with HindIII and NotI, and the EBNA-6 region
inserted into EBO-pLPP, restricted with the same enzymes.
This resulted in removal of amino acids 394–624 of
EBNA-6.
pEBO-GFP-E6D1-206/941–992
The HpaI–XhoI fragment was excised from pBS-GFP-E6
then ligated to pBSGFPL that had previously been restricted
with StuI and XhoI. The EBNA-6 was excised from this
plasmid with HindIII and NotI, and was ligated into EBO-
pLPP that had been restricted with HindIII and NotI. This
allowed the expression of GFP linked to amino acids 207–
940 of EBNA-6 and reconstituted the NLS at 940–943.
pBS-GFPL-E6D1-206/394–624
The pBSGFPL-E6D396-625 construct was digested with
HpaI and NotI, and then fragment inserted into pBSGFPL
that had been restricted with HpaI and NotI. This resulted in
the expression of a fusion of GFP with EBNA-6 amino
acids 207–393 joined with amino acids 625–992.
P3XFLAGCMV10-E3D1-279
The pEGFPC2-EBNA3 plasmid (containing the full-
length EBNA-3 sequence from B95-8) was cut with EcoR1
and the EBNA-3 sequence encoding aa280-944 was isolat-
ed, end-filled with Klenow, and was ligated into
p3XFLAGCMV10, previously cut with BglII and end-filled
with Klenow.
P3XFLAGCMV10-EBNA-6
The pBS-GFP-E6 plasmid (containing the full-length
EBNA-6 sequence from B95-8) was cut with XbaI, and
the EBNA-6 sequence was isolated then religated into
p3XFLAGCMV10, previously cut with XbaI.
PCR
Regions within EBNA-6, encoding aa626-940, were
generated by PCR and cloned into pBS-GFP. The primers
used were E6F1-5VGTTAACCAGTAAACCTCAGTGCT-
TCTGG3V; E6F2-5VGTTAACCTCATATCCAGGATATGC-
K.G. Krauer et al. / Virology292GGG5V; E6F3-5VGTTAACCTTACATCCAGACGTTGCT-
GC3V; E6RNLS-5VTCTAGAGACTTTCTTCTACTCGAG-
GCC3V; E6R2NLS-5VTCTAGAGTCGAGGCCTTTTGCA-
G G G G T G C C TATA A C AT G G 3 V; E 6 R 3 N L S -
5VTCTAGACTCGAGGCCTTTTCATGCTATCTTGTAAC-
TCTAGACTCGAGGCCTTTTCATGCTATCTTGTAACG-
GC3V. Following PCR amplification, the products were
cloned into pGEM-T, amplified, and the inserts excised with
HpaI/XbaI, purified and ligated into the HpaI and XbaI sites
within the polylinker of the pBS-GFP plasmid (there is a stop
codon following the XbaI site in this polylinker). Each of the
pBS-GFP plasmids, containing PCR amplified inserts, were
transiently transfected into HeLa cells, and the association of
the GFP-fusion proteins with nuclear structures were deter-
mined by confocal microscopy.
DNA sequencing
DNA sequencing reactions were performed according to
the protocol in the PRISM Ready Reaction DyeDeoxy
terminator cycle sequencing kit (Applied Biosystems,
Incorp.). The reactions were then analyzed using the auto-
mated Applied Biosystems Model 373A DNA sequencing
system.
Cell lines and maintenance
The EBV-negative Burkitt’s lymphoma (BL) cell line
DG75 (Ben Bassat et al., 1977), the EBV-positive group 1
BL cell line MutuI, the EBV-positive group 3 cell line
MutuIII, and the HeLa cell line were maintained in RPMI
1640 supplemented with 10% fetal calf serum (FCS),
benzylpenicillin (0.7 mg/ml), and streptomycin (1 mg/ml)
at 37 jC in 5% CO2 atmosphere. HeLa cells stably express-
ing GFP-EBNA-6 constructs also had 150 Ag/ml hygrom-
ycin added to the media.
Transfection of HeLa cells
Exponentially growing HeLa cells were transected using
Lipofectamine 2000 (LF2000) reagent (Gibco BRL)
according to the manufacturers protocol. Briefly, the day
before transfection HeLa cells were trypsinized, counted,
and plated at a cell density of 2  105/well in 2.5-ml
RPMI-1640 containing 10% FCS. Plasmid DNA (5 Ag)
was diluted in 250-Al Opti-mem I-reduced serum medium
(Gibco BRL) and mixed with 10-Al LF2000 reagent pre-
diluted in 250-Al Opti-mem I medium. DNA-LF2000
reagent complexes were allowed to form for 20 min at
room temperature (RT) and were then added to the cells
and mixed by gentle rocking. Cells were analyzed for
transient gene expression following 48-h incubation at 37
jC in 5% CO2 atmosphere. For stable cell lines, HeLa
cells were transfected with the episomal vector EBO-
pLPP-based GFP-EBNA-6 deletion constructs and were
then selected in 150 Ag/ml hygromycin until stable cell
lines grew out.Treatment of cells with cell cycle blockers
HeLa cells expressing GFP-E6D1-206/941–992 were
grown on cover slips overnight and were then treated for
24 h with the following drugs: aphidicolin (5 Ag/ml);
colcimide (100 ng/ml); etoposide (1 um); hydroxyurea (2
mM); ICRF (0.5 Ag/ml); mimosine (200 AM), and nocada-
zole (0.5 Ag/ml). Following treatment, the cells were then
processed for direct fluorescent microscopy.
Direct fluorescence microscopy
HeLa cells expressing GFP-EBNA-6 fusion proteins
were grown on cover slips and were then fixed with acetone
(2 min,  20 jC) before being mounted in Vectashield
mounting medium (Vector Laboratories) onto glass slides.
Immunofluorescent images were captured under a Zeiss
Plan Apochromat oil immersion objective (100) with
appropriate filters using EPL-400 Kodak film.
Co-localization Immunofluorescent microscopy
MutuI and MutuIII cells were spotted onto cover slips,
whereas HeLa cells expressing GFP-EBNA-6 fusion pro-
teins were grown on cover slips. The cells were then fixed in
cold methanol ( 20 jC for 5 min) then permeabilized in
cold acetone ( 20 jC) for 2 min. Firstly, the cells were
blocked using 20% FCS/PBS/0.5% Tween 20 for 30 min at
room temperature (RT), and then incubated with anti-SMN
antibody (BD Transduction Laboratories) diluted 1:100 in
blocking buffer (1 h at RT). Slides were washed in PBS (3 
10 min) and were incubated with goat anti-mouse IgG-
Texas Red-X antibody diluted 1:100 (Molecular Probes) for
1 h at RT. The slides were then washed three times with PBS
and mounted in Vectashield mounting medium (Vector
Laboratories). Samples of MutuI and MutuIII cells were
visualized and photographed on a fluorescent microscope.
HeLa cells were scanned using a Bio-Rad MRC 600
confocal microscope. The excitation source was a Laser
Physics 15 mW Krypton–Argon Laser. GFP fluorescence
emission was collected using the standard BHS Block (515-
nm LP). Images were acquired using Confocal Microscope
Operating Software Version 6.03 (COMOS). The acquired
images were then analyzed and processed for presentation
using Confocal Assistant Software Version 3.10 (CAS) in
which single optical sections are shown.
Preparation of nuclear matrix
Nuclear matrix fractions were prepared by a method
similar to that described by Mirkovitch et al. (1984), with
adaptations by Sanchez et al. (1998). DG75 cells (1  107),
transfected with pGFP-EBNA-6, pFLAG-EBNA-3, pGFP-
EBNA-1, or pGFP control vector were washed in PBS and
incubated in PBS containing 0.2% NP-40 (15 min at 4 jC).
Nuclei (N) were collected by centrifugation (600  g for 10
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Nuclei were resuspended in digestion buffer (20 mM Tris–
HCl [pH 7.4], 20 mM KCl, 70 mM NaCl, 10 mM MgCl2,
0.05 mM spermine, 0.125 mM spermidine) containing 1
mM phenylmethylsolfonyl fluoride (PMSF) and subject to
digestion with DNase I (Boehringer Mannheim) (150 U) for
15 min at room temperature. Digested nuclei were collected
by centrifugation (600  g for 10 min) and the supernatant
(NP) collected also. Nuclei were then resuspended in
digestion buffer containing 0.1% digitonin and incubated
at room temperature for 10 min. The insoluble nuclear
material was pelleted and the supernatant-containing lipid
soluble material collected (L). The pelleted material was
extracted in high-salt buffer (2 M NaCl, 20 mM HEPES, pH
7.4, 20 mM EDTA) on ice for 5 min. The nuclear material
was pelleted and the high-salt soluble material (HS) collect-
ed. The pelleted nuclear matrix (M) was washed three times
in 1 M guanidine hydrochloride in digestion buffer (2 min
per wash) and collected by centrifugation (600  g for 10
min) and represented guanidine hydrochloride-washed nu-
clear matrix (GM).
SDS-polyacrylamide gel electrophoresis and
immunoblotting
Cell lysates were prepared by resuspending cells in SDS
sample buffer (2% SDS; 5% a-monothioglycerol; 10%
glycerol; 60 mM Tris–HCl, pH 6.8; 0.001% bromophenol
blue) followed by sonication and heating to 95 jC for 10
min. Protein extracts from 1  106 cells were electrophor-
esed on 7.5% polyacrylamide gels and were then electro-
transferred onto Hybond-ECL nitrocellulose (Amersham,
UK). The membrane was blocked for 1 h at RT with
blocking buffer (5% skim milk in PBS) and then incubated
for 1 h at RT with a-GFP polyclonal antibody (1:5000).
After washing with PBS containing 0.05% Tween 20 (PBS-
Tween), the filters were incubated (1 h at RT) with sheep a-
rabbit IgG HRP (1:1000) (Silenus, Australia). After subse-
quent washing with PBS-Tween, detection was performed
using the ECL method according to the manufacturer’s
instructions (Amersham).
Immunoprecipitations
Immunoprecipitations were performed according to a
modified method of Harlow and Lane (Antibodies, a Labo-
ratory Manual, 1988). Briefly, cells were resuspended in
RIPA lysis buffer (50 mM Tris–HCl, pH 8; 150 mM NaCl;
0.1% SDS; 1% NP-40; 0.5% sodium deoxycholate; 1 mM
PMSF; 10 Ag/ml aprotinin; 10 Ag/ml leupeptin), incubated
on ice for 30 min with occasional mixing, and then centri-
fuged at 10000  g for 10 min at 4 jC. The supernatant was
precleared with either Protein-A-sepharose or protein-G-
sepharose (25 Al/500 Al of supernatant) for 1 h at 4 jC with
constant rocking. Three microgram of appropriate antibody
(anti-GFP) was added to 500 Al of supernatant (5 106 cells)and the mix was incubated for 2 h at 4 jC with rocking.
Twenty-five microliters of either Protein-A-sepharose or
protein-G-sepharose was added and then incubated for 1
h at 4 jC with rocking. The samples were then centrifuged at
10000 g for 1 min, the supernatant discarded, and the pellet
washed three times with 1 ml of RIPA buffer containing 1
mM PMSF, 10 Ag/ml aprotinin, and 10 Ag/ml leupeptin. The
pellet was resuspended in 25-Al SDS-PAGE loading buffer,
heated to 85 jC for 10 min, centrifuged at 10000  g for 5
min, and 10 Al of the supernatant was electrophoresed on
polyacrylamide-SDS gels.Acknowledgments
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